Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus

Journal of Virology

Volumn 82, Issue 17, 2008, Pages 8383-8391

  Zimmerman, Rebekah Stackpole ^a,b,c   Rosenberg, Naomi ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; PROTEIN P19; 4',6 DIAMIDINO 2 PHENYLINDOLE; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; INDOLE DERIVATIVE;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; MOUSE; NONHUMAN; NUCLEOLUS; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VIRUS INFECTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; CELL STRAIN 3T3; CROSS BREEDING; FLOW CYTOMETRY; GENETICS; HETEROZYGOTE; METABOLISM; MOUSE MUTANT; PATHOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

ABELSON MURINE LEUKEMIA VIRUS;

ABELSON MURINE LEUKEMIA VIRUS; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CROSSES, GENETIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FLOW CYTOMETRY; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; HETEROZYGOTE; INDOLES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NIH 3T3 CELLS;

EID: 50149083665     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00348-08     Document Type: Article

References (49)

1. ARF in maintaining nucleolar structure and function. Mol. Cell. Biol. 28:1068-1080.
2. Baughn, L. B., and N. Rosenberg. 2005. Disruption of the Shc/Grb2 complex during Abelson virus transformation affects proliferation, but not apoptosis. J. Virol. 79:2325-2334.
3. Chesebro, B., K. Wehrly, M. Cloyd, W. Britt, J. Portis, J. Collins, and J. Nishio. 1981. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: Friend-specific and FMR-specific antigens. Virology 112:131-144.
4. Arf protein stability. Mol. Cell. Biol. 25:8874-8886.
5. Falini, B., C. Mecucci, E. Tiacci, M. Alcalay, R. Rosati, L. Pasqualucci, R. La Starza, D. Diverio, E. Colombo, A. Santucci, B. Bigerna, R. Pacini, A. Pucciarini, A. Liso, M. Vignetti, P. Fazi, N. Meani, V. Pettirossi, G. Saglio, F. Mandelli, F. Lo-Coco, P. G. Pelicci, and M. F. Martelli. 2005. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352:254-266.
6. Gallagher, S. J., R. F. Kefford, and H. Rizos. 2006. The ARF tumour suppressor. Int. J. Biochem. Cell Biol. 38:1637-1641.
7. Green, P. L., D. A. Kaehler, and R. Risser. 1987. Clonal dominance and progression in Abelson murine leukemia virus lymphomagenesis. J. Virol. 61:2192-2197.
8. Grisendi, S., C. Mecucci, B. Falini, and P. P. Pandolfi. 2006. Nucleophosmin and cancer. Nat. Rev. Cancer 6:493-505.
9. Inoue, K., A. Mallakin, and D. P. Frazier. 2007. Dmp1 and tumor suppression. Oncogene 26:4329-4335.
10. Jacobs, J. J., K. Kieboom, S. Marino, R. A. DePinho, and M. van Lohuizen. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168.
11. Jenab-Wolcott, J., D. Rodriguez-Correa, A. H. Reitmair, T. Mak, and N. Rosenberg. 2000. The absence of Msh2 alters Abelson virus pre-B-cell transformation by influencing p53 mutation. Mol. Cell. Biol. 20:8373-8381.
12. Kamijo, T., S. Bodner, E. van de Kamp, D. H. Randle, and C. J. Sherr. 1999. Tumor spectrum in ARF-deficient mice. Cancer Res. 59:2217-2222.
13. Korgaonkar, C., J. Hagen, V. Tompkins, A. A. Frazier, C. Allamargot, F. W. Quelle, and D. E. Quelle. 2005. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25:1258-1271.
14. Korgaonkar, C., L. Zhao, M. Modestou, and D. E. Quelle. 2002. ARF function docs not require p53 stabilization or Mdm2 relocalization. Mol. Cell. Biol. 22:196-206.
15. Kuo, M. L., W. den Besten, D. Bertwistle, M. F. Roussel, and C. J. Sherr. 2004. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18:1862-1874.
16. ARF without relocation of MDM2 to the nucleolus. Nat. Cell Biol. 3:445-452.
17. Lowe, S. W., and C. J. Sherr. 2003. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet Dev. 13:77-83.
18. Mainville, C. A., K. Parmar, I. Unnikrishnan, L. Gong, G. D. Raffel, and N. Rosenberg. 2001. Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain. J. Virol. 75:1816-1823.
19. Maki, C. G., J. M. Huibregtse, and P. M. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:2649-2654.
20. ARF tumor suppressor are involved in p53-indepcndent apoptosis. Biochem. Biophys. Res. Commun. 301:1000-1010.
21. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
22. Noronha, E. J., K. Hinrichs Sterling, and K. L. Calame. 2003. Increased expression of Bcl-xL and c-Myc is associated with transformation by Abelson murine leukemia virus. J. Biol. Chem. 278:50915-50922.
23. Nozawa, Y., N. Van Belzen, A. C. Van der Made, W. N. Dinjens, and F. T. Bosman. 1996. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J. Pathol. 178:48-52.
24. Park, I. K., S. J. Morrison, and M. F. Clarke. 2004. Bmi1, stem cells, and senescence regulation. J. Clin. Investig. 113:175-179.
25. ARF. Proc. Natl. Acad. Sci. USA 94:669-673.
26. Radfar, A., I. Unnikrishnan, H. W. Lee, R. A. DePinho, and N. Rosenberg. 1998. p19(Arf) induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. USA 95:13194-13199.
27. Reichow, S. L., T. Hamma, A. R. Ferre-D'Amare, and G. Varani. 2007. The structure and function of small nucleolar ribonucleoproteins. Nucleic Acids Res. 35:1452-1464.
28. Rodway, H., S. Llanos, J. Rowe, and G. Peters. 2004. Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene 23:6186-6192.
29. Rosenberg, N., and O. N. Witte. 1980. Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule. J. Virol. 33:340-348.
30. Ink4a interferes with Abelson virus transformation by enhancing apoptosis. J. Virol. 78:3304-3311.
31. Shore, S. K., R. V. Tantravahi, and E. P. Reddy. 2002. Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene 21:8568-8576.
32. Smith, K. S., S. K. Chanda, M. Lingbeek, D. T. Ross, D. Botstein, M. van Lohuizen, and M. L. Cleary. 2003. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol. Cell 12:393-400.
33. Sreeramaneni, R., A. Chaudhry, M. McMahon, C. J. Sherr, and K. Inoue. 2005. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol. Cell. Biol. 25:220-232.
34. Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
35. Subong, E. N., M. J. Shue, J. I. Epstein, J. V. Briggman, P. K. Chan, and A. W. Partin. 1999. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 39:298-304.
36. Sugimoto, M., M. L. Kuo, M. F. Roussel, and C. J. Sherr. 2003. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11:415-424.
37. Tago, K., S. Chiocca, and C. J. Sherr. 2005. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc. Natl. Acad. Sci. USA 102:7689-7694.
38. Thome, K. C., A. Radfar, and N. Rosenberg. 1997. Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. J. Virol. 71:8149-8156.
39. Unnikrishnan, I., A. Radfar, J. Jenab-Wolcott, and N. Rosenberg. 1999. p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Mol. Cell. Biol. 19:4825-4831.
40. Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11:281-288.
41. Warren, D., D. S. Griffin, C. Mainville, and N. Rosenberg. 2003. The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus. J. Virol. 77:4617-4625.
42. Weber, J. D., J. R. Jeffers, J. E. Rehg, D. H. Randle, G. Lozano, M. F. Roussel, C. J. Sherr, and G. P. Zambetti. 2000. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 14:2358-2365.
43. Weber, J. D., M. L. Kuo, B. Bothner, E. L. DiGiammarino, R. W. Kriwacki, M. F. Roussel, and C. J. Sherr. 2000. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20:2517-2528.
44. Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:20-26.
45. Whitlock, C. A., and O. N. Witte. 1981. Abelson virus-infected cells can exhibit restricted in vitro growth and low oncogenic potential. J. Virol. 40:577-584.
46. Whitlock, C. A., S. F. Ziegler, and O. N. Witte. 1983. Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes. Mol. Cell. Biol. 3:596-604.
47. Wong, K. K., X. Zou, K. T. Merrell, A. J. Patel, K. B. Marcu, S. Chellappan, and K. Calame. 1995. v-Abl activates c-myc transcription through the E2F site. Mol. Cell. Biol. 15:6535-6544.
48. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
49. Zou, X., S. Rudchenko, K. Wong, and K. Calame. 1997. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases. Genes Dev. 11:654-662.